RxDoctor Payments Data

Kumar Patel, MD

Family Medicine · Bloomfield, NJNPI 1952898140

Payments from drug & device makers

$1,521in general payments, 2019–2025

Across 52 payments — averaging $29.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$216
  • Medtronic$165
  • Inari Medical, Inc.$133
  • Abiomed$132
  • VYNE Pharmaceuticals Inc.$125
  • Boehringer Ingelheim$112
  • plus $638 from 15 others

What the payments were for

  • Food & beverage$1,521100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,521 in reported general payments places this provider in the 70th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$264,844
Medicare patients
306
Services billed
3,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol124$135,781
JardianceEmpagliflozin142$127,398
JanuviaSitagliptin Phosphate76$87,508
EliquisApixaban84$81,087
MounjaroTirzepatide50$66,205
OzempicSemaglutide34$48,193
RybelsusSemaglutide26$46,362
Trelegy ElliptaFluticasone/Umeclidin/Vilanter46$41,492
Trijardy XrEmpaglifloz/Linaglip/Metformin31$40,900
TradjentaLinagliptin43$39,715
ProliaDenosumab18$30,546
EntrestoSacubitril/Valsartan14$24,117
XareltoRivaroxaban29$23,101
JanumetSitagliptin Phos/Metformin Hcl29$22,302
Xigduo XrDapaglifloz Propaned/Metformin14$12,297

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Trijardy Xr, Tradjenta, Glyxambi$112$219,412229 claims
AstraZenecaFarxiga, Symbicort$216$141,411138 claims
PfizerEliquis, Abrysvo$30$86,492101 claims
Lilly USA, LLCMounjaro$66$66,20550 claims
GSKTrelegy Ellipta, Breo Ellipta$98$49,75867 claims
AmgenProlia$65$30,54618 claims
NovartisEntresto$20$24,11714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Bloomfield

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →